

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

BJELDANES, et al.

Serial No.: 10/664,991

Filing Date: September 16, 2003

For: *3,3'-Diindolylmethane Antiandrogenic Compositions*

Examiner: BETTON, Timothy E.

Art Unit: 1627

Conf. No.: 4613

CERTIFICATE OF ELECTRONIC TRANSMISSION

I hereby certify that this correspondence, including listed enclosures, is being electronically transmitted in Portable Document Form (PDF) through EFS-Web via Hyper Text Transfer Protocol to the United States Patent and Trademark Office's Patent Electronic Business Center on:

Dated: AUGUST 24, 2010

Signed: 
Nicholas Garnett

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RESPONSE UNDER 37 C.F.R. § 1.116

Sir:

This paper is in response to a final Office Action mailed February 24, 2010. This response is being submitted on or before August 24, 2010, along with payment of the required extension of time fee, thereby making this a timely response. Applicant respectfully requests that the Examiner amend the present application in the manner set forth in this Amendment.

Applicant submits that this amendment after final rejection at least places this application in better form for appeal. Applicant respectfully submits that this amendment should only require a cursory review because the claim amendments presented herein do not add any new features and/or do not significantly alter the scope of the claims. Consequently, the claim amendments should not require any further search by the Examiner. This amendment is necessary as it clarifies and/or narrows the issues for consideration by the Board and was not earlier presented because Applicant believed that the prior response(s) placed this application in condition for allowance, for at least the reasons set forth in those response(s). Accordingly, entry of the present

Amendment, as an earnest attempt to advance prosecution and/or to reduce the number of issues, is requested under 37 C.F.R. §1.116.

Applicants believe no additional fees are due. Nonetheless, Applicants authorize the Commissioner to charge any fees which may be required, including extension fees and excess claims fees, or credit any overpayment, to Deposit Account No. 50-2387 (Our Order No. 24077.019; Our Docket No.: 21000/US).

Please amend the application as follows:

Listing of claims begins on page 3 of this paper.

Remarks begin on page 7 of this paper.